Get startedLog in
    Picture of Ipsen SA logo

    IPN — Ipsen SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Ipsen Withdraws Tazverik® (tazemetostat) In Follicular Lymphoma, Epithelioid Sarcoma

    Picture of Ipsen SA logoIpsen SA
    09/03/2026 06:04
    March 9 (Reuters) - Ipsen SA IPN.PA:

IPSEN VOLUNTARILY WITHDRAWS TAZVERIK® (TAZEMETOSTAT) IN FOLLICULAR LYMPHOMA AND EPITHELIOID SARCOMA

WORKS WITH U.S. FDA TO EXECUTE TAZVERIK WITHDRAWAL

WITHDRAWAL NOT EXPECTED TO IMPACT COMPANY FINANCIAL GUIDANCE

IDMC ADVISES RISKS MAY OUTWEIGH BENEFITS DUE TO SECONDARY HEMATOLOGIC MALIGNANCIES

Source text: ID:nGNE7PzyTz

Further company coverage: IPN.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Ipsen SA

    See all news